Alnylam Pharmace. buy stefan
Start price
01.10.19
/
50%
€68.16
Target price
04.11.21
-
Performance (%)
134.45%
End price
05.11.21
€159.80
Summary
This prediction ended on 05.11.21 with a price of €159.80. With a performance of 134.45% the BUY prediction by stefan was a big success. stefan has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 0.749% | 0.749% | 38.074% | 52.373% |
| iShares Core DAX® | 0,44 % | 3,03 % | 12,68 % | 49,79 % |
| iShares Nasdaq 100 | 3,82 % | 4,07 % | 33,15 % | 88,25 % |
| iShares Nikkei 225® | 1,15 % | 6,90 % | 45,49 % | 61,92 % |
| iShares S&P 500 | 2,37 % | 2,68 % | 25,69 % | 63,54 % |
Comments by stefan for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.
Die von stefan gewählte maximale Laufzeit wurde überschritten